Compare PULM & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PULM | CLGN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 7.0M |
| IPO Year | 2013 | 2015 |
| Metric | PULM | CLGN |
|---|---|---|
| Price | $1.69 | $0.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 37.5K | ★ 40.1K |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,910,000.00 | N/A |
| Revenue This Year | N/A | $240.45 |
| Revenue Next Year | N/A | $38.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5069.93 | N/A |
| 52 Week Low | $1.16 | $0.27 |
| 52 Week High | $6.15 | $3.23 |
| Indicator | PULM | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 36.97 |
| Support Level | $1.59 | $0.29 |
| Resistance Level | $1.88 | $0.44 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 41.18 | 0.23 |
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.